Induction Therapy for Lung Transplantation in COPD: Analysis of the UNOS Registry

Joseph S. Duffy, Dmitry Tumin, Amy Pope-Harman, Bryan A. Whitson, Robert Higgins, Don Hayes,

Research output: Contribution to journalArticle

Abstract

Although studies demonstrate that induction therapy improves outcomes after lung transplantation, its influence on survival in patients with chronic obstructive pulmonary disease (COPD) is not clear. The United Network for Organ Sharing database was queried to obtain data regarding adult patients with COPD receiving lung transplant between May 2005 and June 2014. Therapies evaluated include anti-thymocyte globulin, anti-lymphocyte globulin, thymoglobulin, basiliximab, and alemtuzumab. Data were categorized based on receiving induction (INDUCED) and no induction (NONE). Kaplan–Meier plots, Cox proportional hazards models of patient survival, and competing-risks regression models for secondary endpoints were utilized. A total of 3,405 patients who underwent lung transplantation for COPD were enrolled with 1,761 (52%) receiving induction therapy. Of INDUCED, 1,146 (65%) received basiliximab, 380 (22%) received alemtuzumab, and 235 (13%) received a polyclonal preparation. The hazard ratio for INDUCED vs. NONE was 0.793 (95% CI = 0.693, 0.909; p = 0.001) in the fully adjusted Cox model. A multivariable competing-risks model also found a protective influence of induction therapy with respect to delayed onset of bronchiolitis obliterans syndrome after transplantation (SHR = 0.801; 95% CI = 0.694, 0.925; p = 0.003). In a cohort of recently transplanted patients with COPD, there appears to be a benefit from contemporary induction agents with no concurrent increase in the risk of death due to infection.

Original languageEnglish (US)
Pages (from-to)1-6
Number of pages6
JournalCOPD: Journal of Chronic Obstructive Pulmonary Disease
DOIs
StateAccepted/In press - Jan 1 2016

Fingerprint

Lung Transplantation
Chronic Obstructive Pulmonary Disease
Registries
Proportional Hazards Models
Bronchiolitis Obliterans
Therapeutics
Antilymphocyte Serum
Survival
Globulins
Transplantation
Databases
Lymphocytes
Transplants
Lung
Infection

Keywords

  • chronic obstructive pulmonary disease
  • immunosuppression
  • induction
  • lung transplantation
  • mortality
  • survival

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Induction Therapy for Lung Transplantation in COPD : Analysis of the UNOS Registry. / Duffy, Joseph S.; Tumin, Dmitry; Pope-Harman, Amy; Whitson, Bryan A.; Higgins, Robert; Hayes, Don.

In: COPD: Journal of Chronic Obstructive Pulmonary Disease, 01.01.2016, p. 1-6.

Research output: Contribution to journalArticle

Duffy, Joseph S. ; Tumin, Dmitry ; Pope-Harman, Amy ; Whitson, Bryan A. ; Higgins, Robert ; Hayes, Don. / Induction Therapy for Lung Transplantation in COPD : Analysis of the UNOS Registry. In: COPD: Journal of Chronic Obstructive Pulmonary Disease. 2016 ; pp. 1-6.
@article{8da295b624834f12b52ba7494ae3eefa,
title = "Induction Therapy for Lung Transplantation in COPD: Analysis of the UNOS Registry",
abstract = "Although studies demonstrate that induction therapy improves outcomes after lung transplantation, its influence on survival in patients with chronic obstructive pulmonary disease (COPD) is not clear. The United Network for Organ Sharing database was queried to obtain data regarding adult patients with COPD receiving lung transplant between May 2005 and June 2014. Therapies evaluated include anti-thymocyte globulin, anti-lymphocyte globulin, thymoglobulin, basiliximab, and alemtuzumab. Data were categorized based on receiving induction (INDUCED) and no induction (NONE). Kaplan–Meier plots, Cox proportional hazards models of patient survival, and competing-risks regression models for secondary endpoints were utilized. A total of 3,405 patients who underwent lung transplantation for COPD were enrolled with 1,761 (52{\%}) receiving induction therapy. Of INDUCED, 1,146 (65{\%}) received basiliximab, 380 (22{\%}) received alemtuzumab, and 235 (13{\%}) received a polyclonal preparation. The hazard ratio for INDUCED vs. NONE was 0.793 (95{\%} CI = 0.693, 0.909; p = 0.001) in the fully adjusted Cox model. A multivariable competing-risks model also found a protective influence of induction therapy with respect to delayed onset of bronchiolitis obliterans syndrome after transplantation (SHR = 0.801; 95{\%} CI = 0.694, 0.925; p = 0.003). In a cohort of recently transplanted patients with COPD, there appears to be a benefit from contemporary induction agents with no concurrent increase in the risk of death due to infection.",
keywords = "chronic obstructive pulmonary disease, immunosuppression, induction, lung transplantation, mortality, survival",
author = "Duffy, {Joseph S.} and Dmitry Tumin and Amy Pope-Harman and Whitson, {Bryan A.} and Robert Higgins and Don Hayes,",
year = "2016",
month = "1",
day = "1",
doi = "10.3109/15412555.2015.1127340",
language = "English (US)",
pages = "1--6",
journal = "COPD: Journal of Chronic Obstructive Pulmonary Disease",
issn = "1541-2555",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Induction Therapy for Lung Transplantation in COPD

T2 - Analysis of the UNOS Registry

AU - Duffy, Joseph S.

AU - Tumin, Dmitry

AU - Pope-Harman, Amy

AU - Whitson, Bryan A.

AU - Higgins, Robert

AU - Hayes,, Don

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Although studies demonstrate that induction therapy improves outcomes after lung transplantation, its influence on survival in patients with chronic obstructive pulmonary disease (COPD) is not clear. The United Network for Organ Sharing database was queried to obtain data regarding adult patients with COPD receiving lung transplant between May 2005 and June 2014. Therapies evaluated include anti-thymocyte globulin, anti-lymphocyte globulin, thymoglobulin, basiliximab, and alemtuzumab. Data were categorized based on receiving induction (INDUCED) and no induction (NONE). Kaplan–Meier plots, Cox proportional hazards models of patient survival, and competing-risks regression models for secondary endpoints were utilized. A total of 3,405 patients who underwent lung transplantation for COPD were enrolled with 1,761 (52%) receiving induction therapy. Of INDUCED, 1,146 (65%) received basiliximab, 380 (22%) received alemtuzumab, and 235 (13%) received a polyclonal preparation. The hazard ratio for INDUCED vs. NONE was 0.793 (95% CI = 0.693, 0.909; p = 0.001) in the fully adjusted Cox model. A multivariable competing-risks model also found a protective influence of induction therapy with respect to delayed onset of bronchiolitis obliterans syndrome after transplantation (SHR = 0.801; 95% CI = 0.694, 0.925; p = 0.003). In a cohort of recently transplanted patients with COPD, there appears to be a benefit from contemporary induction agents with no concurrent increase in the risk of death due to infection.

AB - Although studies demonstrate that induction therapy improves outcomes after lung transplantation, its influence on survival in patients with chronic obstructive pulmonary disease (COPD) is not clear. The United Network for Organ Sharing database was queried to obtain data regarding adult patients with COPD receiving lung transplant between May 2005 and June 2014. Therapies evaluated include anti-thymocyte globulin, anti-lymphocyte globulin, thymoglobulin, basiliximab, and alemtuzumab. Data were categorized based on receiving induction (INDUCED) and no induction (NONE). Kaplan–Meier plots, Cox proportional hazards models of patient survival, and competing-risks regression models for secondary endpoints were utilized. A total of 3,405 patients who underwent lung transplantation for COPD were enrolled with 1,761 (52%) receiving induction therapy. Of INDUCED, 1,146 (65%) received basiliximab, 380 (22%) received alemtuzumab, and 235 (13%) received a polyclonal preparation. The hazard ratio for INDUCED vs. NONE was 0.793 (95% CI = 0.693, 0.909; p = 0.001) in the fully adjusted Cox model. A multivariable competing-risks model also found a protective influence of induction therapy with respect to delayed onset of bronchiolitis obliterans syndrome after transplantation (SHR = 0.801; 95% CI = 0.694, 0.925; p = 0.003). In a cohort of recently transplanted patients with COPD, there appears to be a benefit from contemporary induction agents with no concurrent increase in the risk of death due to infection.

KW - chronic obstructive pulmonary disease

KW - immunosuppression

KW - induction

KW - lung transplantation

KW - mortality

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=84958527540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958527540&partnerID=8YFLogxK

U2 - 10.3109/15412555.2015.1127340

DO - 10.3109/15412555.2015.1127340

M3 - Article

C2 - 26829054

AN - SCOPUS:84958527540

SP - 1

EP - 6

JO - COPD: Journal of Chronic Obstructive Pulmonary Disease

JF - COPD: Journal of Chronic Obstructive Pulmonary Disease

SN - 1541-2555

ER -